We present an integrated valuation model for diseases that pose some chance of death. The model extends the standard one-period value-of-statistical-life model to three health prospects: healthy, ill, and dead. We derive willingness-to-pay values for preven- tion eorts that reduce a disease’s incidence rate as well as for treatments that lower the corresponding health deterioration and mortality rates. We find that the demand value of prevention always exceeds that of treatment. People often overweight small risks and underweight large ones. We use the rank dependent utility framework to explore how the demand for prevention and treatment alters when people evaluate probabilities in a non-linear manner. For incidence and mortality rates ass...
Cancer is one of the diseases which are flourishing very rapidly throughout the world due to which m...
Both actual and expected morbidity systematically affect individuals’ demands for both life-saving p...
This paper examines the value of reducing foodborne risk. Previous research on the valuation of heal...
We present an integrated valuation model for diseases that pose some chance of death. The model exte...
We present an integrated valuation model for diseases that are life-threatening. The model extends t...
We use stated-preference methods to estimate the cancer Value per Statistical Life (VSL) and Value p...
A choice model based on utility in each of a sequence of prospective future health states permits us...
This paper develops and applies an integrated model of mortality and morbidity valuation that is con...
This paper develops and applies an integrated model of human mortality and morbidity valuation that ...
Much of the literature on the value of life is based on the valuation of small reductions in mortali...
The Value of a Statistical Life (VSL) is a widely used measure of the value of mortality risk reduct...
This paper develops and applies an integrated model of mortality and morbidity valuation that is con...
In cost-effectiveness analysis, the valuing of costs and health effects over time remains a controve...
In cost-effectiveness analysis, the valuing of costs and health effects over time remains a controve...
Cancer is one of the diseases which are flourishing very rapidly throughout the world due to which m...
Both actual and expected morbidity systematically affect individuals’ demands for both life-saving p...
This paper examines the value of reducing foodborne risk. Previous research on the valuation of heal...
We present an integrated valuation model for diseases that pose some chance of death. The model exte...
We present an integrated valuation model for diseases that are life-threatening. The model extends t...
We use stated-preference methods to estimate the cancer Value per Statistical Life (VSL) and Value p...
A choice model based on utility in each of a sequence of prospective future health states permits us...
This paper develops and applies an integrated model of mortality and morbidity valuation that is con...
This paper develops and applies an integrated model of human mortality and morbidity valuation that ...
Much of the literature on the value of life is based on the valuation of small reductions in mortali...
The Value of a Statistical Life (VSL) is a widely used measure of the value of mortality risk reduct...
This paper develops and applies an integrated model of mortality and morbidity valuation that is con...
In cost-effectiveness analysis, the valuing of costs and health effects over time remains a controve...
In cost-effectiveness analysis, the valuing of costs and health effects over time remains a controve...
Cancer is one of the diseases which are flourishing very rapidly throughout the world due to which m...
Both actual and expected morbidity systematically affect individuals’ demands for both life-saving p...
This paper examines the value of reducing foodborne risk. Previous research on the valuation of heal...